Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

MD
Pediatrix Medical Group, Inc.
stock NYSE

Market Open
Jun 30, 2026 1:12:13 PM EDT
25.17USD+1.964%(+0.48)201,960
25.15Bid   25.20Ask   0.05Spread
Pre-market
Jun 30, 2026 9:24:30 AM EDT
24.90USD+0.851%(+0.21)1,490
After-hours
Jun 29, 2026 4:10:30 PM EDT
24.69USD+0.081%(+0.02)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsTrends
MD Reddit Mentions
Subreddits
Limit Labels     

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.
Take me to the API
MD Specific Mentions
As of Jun 30, 2026 1:12:09 PM EDT (<1 min. ago)
Includes all comments and posts. Mentions per user per ticker capped at one per hour.
1 hr ago • u/mxg67777 • r/whitecoatinvestor • ltd_coverage_in_residency • C
Who is "they"? LTD during residency should not be a problem and most don't seem to have an issue. Talk to someone like Scott at MD Financial Services.
sentiment 0.58
15 hr ago • u/Background_Entry9588 • r/whitecoatinvestor • optimizing_financial_future_as_a_hs_student • Personal Finance and Budgeting • B
This post is likely very unusual for this sub but I have been reading through here and found the advice very helpful. I have just graduated high school and have been accepted into a BS/MD program which gives me guaranteed admission to medical school given I meet GPA requirements (3.7 and no MCAT). Recently through this program I was also able to get a full cost of attendance scholarship for undergrad and medical school.
I am extremely grateful to be put in such a situation and the lack of debt has lead me to think about my financial future. What can I do over the next 8 years to optimize my finances? Should I get a job, invest, etc.? Are there any choices I could make today or in the next couple years that will help my future self?
I understand that I should take the next 8 years to study, learn, and become the best doctor I can. But given my lack of stress for medical school admissions and debt I was wondering what else I could do to set myself up.
sentiment 0.86
19 hr ago • u/hseeman_sf • r/investing • how_to_read_10k_without_being_burned_the_shit_out • C
There are are number of things you need to look at in 10K, not just in isolation but reading 2-3 years of 10Ks sequentially, very hard to do it without tools. That said, LLMs are great at precisely this kind of work. You could ask the LLM to do the following (this is not an exhaustive list by any means, add/delete as you see fit for your own process):
* **Gross Margin Trajectory:** Extract 3-year gross margins; flag any compression relative to revenue growth.
* **Operating Leverage:** Identify fixed vs. variable costs and evidence of declining customer acquisition costs.
* **Capital Efficiency:** Calculate Return on Invested Capital (ROIC) and track CapEx as a percentage of revenue growth.
* **Shareholder Dilution:** Calculate YoY share count growth and Stock-Based Compensation (SBC) as a percentage of operating cash flow.
* **Customer Concentration:** Flag any single client accounting for >10% of total revenue.
* **Accounting Red Flags:** Identify changes in revenue recognition (Notes 1/2) or shifts toward capitalizing rather than expensing development costs.
* **Unique Vulnerabilities:** Extract non-boilerplate risks (e.g., single-supplier reliance, third-party platform dependency).
* **Narrative Drift:** Compare the MD&A to the prior year and list any strategic initiatives that quietly disappeared.
sentiment 0.91
23 hr ago • u/adjust_your_set • r/investing • how_to_read_10k_without_being_burned_the_shit_out • C
Exactly. 10-k information is for institutional analysts and big investors so they can tweak the risks and assumptions in their earnings models.
The average retail or individual investor isn’t going to gain much investing insight from those disclosures, or make investment decisions based on what is in the MD&A.
sentiment 0.32
1 day ago • u/Curious_Eye4151 • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
Or anesthesia. I hear they have better flex than the average MD?
sentiment 0.44
1 day ago • u/Curious_Eye4151 • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
This is a hot take, for sure. RN here, work in a unionized hospital, three days a week, no call, no weekends, gross pay is $176K which is more than enough for my family of four, max both 403b and 457 retirement account. I love that with a nursing career, I have more time freedom and flexibility. Will retire at 48 with enough invested in index funds.
Only you can decide if going the pharmacy route is the best option for you, but if you want freedom/flexibility, I’d beg to differ that the MD/pharmacy route offers that. Could be wrong though…..
sentiment 0.72
1 day ago • u/thanatos0320 • r/investing • how_to_read_10k_without_being_burned_the_shit_out • C
Financials, MD&A, and that's it.. you could check out the notes if you wanted as well, but there is no need to read everything in the notes. There is also point in reading the risk every single time either.
sentiment -0.60
1 day ago • u/konamul • r/stocks • how_to_read_10k_without_being_burned_the_shit_out • C
To be honest you should use AI, especially considering institutional investors already do. It’s not like they have a junior analyst sitting reading a 100 pages nowadays. But because the context is so large AI can hallucinate. So they create a templatized report and use parsing algo data streams to ensure accuracy like [AlphaCreek](https://www.alphacreek.ai). The reason you need to specifically parse it is because if you only want to know about management sentiment, LLM should only pull the MD&A the rest would be bloat. If LLMs are not pulling the exact parsed area, it will just try to stitch something that “makes sense” throughout the 100 pages - where people are saying it hallucinates. It also saves significant token consumption as you can imagine it only reads the paragraph needed and not the entire document
sentiment 0.92
1 day ago • u/steady_compounder • r/stocks • how_to_read_10k_without_being_burned_the_shit_out • C
You do not need to read a 10-K like a novel. I would start with the business summary, MD&A, segment results, cash flow, and then only dive into the risk factors or footnotes when something looks off. The real goal is not to consume 100 pages, it is to find what changed, what management is emphasising, and what could break the thesis.
sentiment 0.40
1 day ago • u/Heavy_Nothing_1158 • r/stocks • how_to_read_10k_without_being_burned_the_shit_out • C
Two things made 10-Ks less miserable for me: don’t read them front-to-back, and don’t start with Risk Factors (that section is basically corporate anxiety fan fiction).
For Apple I’d usually do:
1. MD&A first: revenue by segment/geography, gross margin, buybacks, services growth.
2. Notes: debt, share count, R&D, legal/regulatory stuff.
3. Risk Factors only as a diff: what changed vs last year?
Then keep a tiny checklist: “what would make me wrong?” If you can answer that after 30–45 minutes, you probably got more value than from three heroic Twitter threads and one espresso-fueled hallucination.
sentiment 0.55
1 day ago • u/viserys8769 • r/stocks • how_to_read_10k_without_being_burned_the_shit_out • C
You’ve been opening it for 3 years and suddenly you feel it’s too long?
Read the MD&A that should be enough.
sentiment 0.00
2 days ago • u/markermal3 • r/Wallstreetsilver • bullionstatsnet_silver_stock_trends_from • :DD::Spacer:DUE DILIGENCE • B
This is based on 702 tracked silver products from APMEX updated 5-6pm CST. To see an explanation on how this information is retrieved refer to the 'How we compile the daily silver stock trends' section on the [BullionStats.net site](https://bullionstats.net). There you can find data going back as far as 11/15/25 on inventory or silver premium trends
Total oz purchased since tracking started 11/15/25: 4,590,756.65
Total in-stock oz tracked: 681,893.05
Tracked oz added (24h): 0
Tracked oz removed (24h): 4,900.37
Number restocked since OOS: 0
Number now out of stock: 2
Top 15 cumulative oz sold for tracked products:
1. [530 oz: 10 oz Silver Bar - APMEX](https://www.apmex.com/product/27087/10-oz-silver-bar-apmex)
2. [400 oz: 100 oz Silver Bar - PAMP Suisse (Serialized)](https://www.apmex.com/product/196345/100-oz-silver-bar-pamp-suisse-serialized)
3. [321.5 oz: 1 kilo Cast-Poured Silver Bar - APMEX](https://www.apmex.com/product/210657/1-kilo-cast-poured-silver-bar-apmex)
4. [284 oz: 2026 Great Britain 1 oz Silver Britannia BU](https://www.apmex.com/product/318588/2026-great-britain-1-oz-silver-britannia-bu)
5. [280 oz: 10 oz Cast-Poured Silver Bar - APMEX](https://www.apmex.com/product/210655/10-oz-cast-poured-silver-bar-apmex)
6. [261 oz: 1 oz Silver Bar - 2026 APMEX Year of the Horse (Series 2)](https://www.apmex.com/product/314686/1-oz-silver-bar-2026-apmex-year-of-the-horse-series-2)
7. [225.05 oz: 1 kilo Silver Bar - Secondary Market](https://www.apmex.com/product/75361/1-kilo-silver-bar-secondary-market)
8. [210 oz: 5 oz Silver Bar - 2026 APMEX Year of the Horse (Series 2)](https://www.apmex.com/product/314687/5-oz-silver-bar-2026-apmex-year-of-the-horse-series-2)
9. [200 oz: 100 oz Silver Bar - APMEX (Struck)](https://www.apmex.com/product/73165/100-oz-silver-bar-apmex-struck)
10. [180 oz: American Silver Eagles (Random Year, 20-Coin MintDirect® Tube)](https://www.apmex.com/product/189172/american-silver-eagles-random-year-20-coin-mintdirect-tube)
11. [160.75 oz: 1 kilo Silver Bar - APMEX (Stackable)](https://www.apmex.com/product/51412/1-kilo-silver-bar-apmex-stackable)
12. [140 oz: 2026 1 oz Silver Eagles (20-Coin MD Premier + PCGS FS® Tube)](https://www.apmex.com/product/316710/2026-1-oz-silver-eagles-20-coin-md-premier-pcgs-fs-tube)
13. [135 oz: 1 oz Silver Round - Peace Dollar](https://www.apmex.com/product/170607/1-oz-silver-round-peace-dollar)
14. [100 oz: 100 oz Silver Bar - Johnson Matthey](https://www.apmex.com/product/35629/100-oz-silver-bar-johnson-matthey)
15. [100 oz: 10 oz Silver Bar - 2026 APMEX Year of the Horse (Series 2)](https://www.apmex.com/product/314688/10-oz-silver-bar-2026-apmex-year-of-the-horse-series-2)
sentiment 0.88
2 days ago • u/loganhughes32 • r/Pmsforsale • wts_gold_and_silver • B
[PROOF](https://coindex.app/photo/P6eSttH)
[ALBUM](https://coindex.app/a/8J1i9P)
4 x 1/10th AGE (1998/2011/2016/2024) $450 per
2017 PCGS MS69 First Strike Panda $90
5 x Pandas (2015/2016/2017/2018/2023) $75 per
9 x 1oz Maples (2008/2013/2019x4/2022/2026x2) $62 per
2016 1oz reverse proof maple panda privy $80
125th anniversary Perth Mint reverse proof 1oz $80
4 x 1oz 2014 Royal mint proof like year of horse $62 per
Prices are firm, I don’t want to make any deals or pay for shipping thanks
$7 ground advantage $12 priority. Will provide tracking link after payment. Shipped out tomorrow from MD. Packages will be dropped off to currier clerk and I will not be liable after packages enter usps system. I will clarify this during chat per sub rules.
Payments accepted- Zelle strongly preferred PP/Venmo/Cash app
Thank you and have a great day…..Logan
sentiment 0.94
2 days ago • u/rageenk • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
It’s actually incredible that you got an acceptance to an MD with zero commitment at all to medicine. Goes to show how subjective admissions is
sentiment 0.68
2 days ago • u/leafytimes • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
Lots of self-immolating MD’s here. You don’t have to work 100+ hours a week and be miserable if you are an MD. Plenty of part-time docs out there happy with their about $200k/year income. Family med ain’t it. Urgent care is not a specialty. You want to work hard and find something like outpatient psych in a stable setting.
I also wonder if you have looked into nurse anesthetist programs.
Pharmacists seem miserable but maybe they are different in Canada.
sentiment 0.45
2 days ago • u/Accomplished_Net5537 • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
I am a hospital clinical pharmacist and, while I enjoy my job most days, I tell people that if you can see yourself doing anything but pharmacy, do NOT go to pharmacy school. The debt is just not worth it honestly for the pay that hasn’t increased in decades and absolutely zero upward mobility in pay unless you move into industry. I also think you would have difficulty finding a job you want in the US as a foreign grad as it’s already pretty saturated.
My husband is an MD, went to med school after finishing pharmacy school and realizing he hated it. Would have saved us a lot of loan money if he just went to med school first lol. Others have commented on the choice for MD or not, so I’ll just leave it at that.
sentiment -0.67
2 days ago • u/Czechaneena • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
Most of the responses suck which is kind of surprising.
I am a PGY5 fellow from and in a US MD program. Honestly, it sounds like you don’t want to do medicine as a whole. Medical school, residency, and fellowship all suck. You don’t get paid much through the latter and the loans are stressful. Sure, one day you can make good money. That money doesn’t come super easy though. You still have to work a lot to make those high salaries. Part time chill gigs exist but they’re not common and especially someone who has all those loans who would qualify for federal forgiveness, you will need to work a lot to repay that. I wasn’t 100% that I wanted to do medicine and while I enjoy most of it I do get really upset at times when I’m still in training all these years and have loans and can’t buy a house and have a 17 year old car and yadda yadda. It’s a long and arduous road that may be worth it in the end but shouldn’t be done unless you’re aware of all of the problems.
Also, $450+ is a shit ton of loans that you will not pay back easily. That needs forgiveness or a really high paying specialty.
What’s the process of doing Canadian med school? I know some people from Canada or UK who are in US residency.
sentiment 0.37
2 days ago • u/visacha13 • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
I wouldn't go through medical school with the debt you get to do primary care. If your aspirations are primary care, don't do MD/DO
sentiment 0.60
2 days ago • u/Secret_Swordfish4121 • r/ValueInvesting • the_case_on_salesforce_stock_crm • Stock Analysis • B
Because a surprising number of people own this stock (or its ETFs) without quite knowing what it sells, here is a simple breakdown first.
Salesforce rents software seats to companies' sales, service, and marketing teams. When a salesperson logs a call, a support rep opens a ticket, or a marketer fires off a campaign, the system they're clicking around in is often Salesforce (the customer database plus the workflow built on top of it). "CRM" literally stands for Customer Relationship Management, sold as a subscription, priced per user, per month ("per seat"). Over the years they bolted on Slack (chat), Tableau (dashboards), MuleSoft (data plumbing), and now Agentforce (AI "agents" that do some of that work automatically). That's the whole company: \~95% of revenue is subscription, almost all of it enterprises renting seats.
I've done a deep dive on the 10-Q, filed May 28, 2026, covering Q1 2026 (the quarter ending April 30, 2026) & some more!
The interesting thing about Salesforce right now is that it's the mirror image of the hot growth stocks people usually dissect here, a profit-and-cash machine the market is treating like a melting ice cube.
**TL;DR**
* Q1 2026 looked strong on the surface, revenue **$11,133M** (**+13.27% YoY**), operating margin **21.08%**, diluted EPS **$2.42** (**+52.2% YoY**), but read the fine print! The **13%** top line is flattered by acquisitions (Informatica alone added \~**$444M**), and net income is flattered by a **$558M** one-time investment gain and a partly debt-funded **$25B** buyback. The cleaner read is cRPO **+14%** and a **\~21%** operating margin.
* **The case for it:** Cheap vs its own history (**\~3.7x** EV/sales, **\~18x** trailing earnings), expanding margins, \~**$14**.**4B/yr** of free cash flow, a shrinking share count, and a real (if unpriced) AI option in Agentforce.
* **The case against it**: Organic growth is high-single-digits and leans on M&A to look double-digit; the company tripled its debt to **\~$39.5B**, issuing **$25B** of senior notes to fund a buyback of stock at prices well above today's; and the core per-seat model is exactly what AI agents threaten. Management itself flags "decreases in the number of users at our customers" as an attrition risk.
* At **$158.37** (June 26 close), **\~819M** shares post-buyback implies **\~$130B** market cap, **\~$157B** EV. My scenario math lands a base-case fair value of **\~$140–173**, so today's price sits in the upper half of fair. The game again is whether AI is a tailwind it monetizes or a tax on the seats it sells.
**The numbers are strong, but read them carefully!**
Q1 2026 (quarter ended April 30, 2026) vs the year-ago quarter:
* Revenue **$11,133M**, up **13.27%** YoY (**$9,829M** a year ago)
* Income from operations **$2,347M**, a **21.08%** operating margin, up from **19.76%** (**$1,942M**)
* Net income **$2,107M** (**+36.73%**)
* Diluted EPS **$2.42** vs **$1.59** (**+52.2%**)
* Effective tax rate **\~23%**, a clean and normal rate (no distortion here)
Three flags I need to mention, because the headline overstates the underlying business:
1. The **13%** growth is partly bought, not earned. The filing lists three recent deals baked into the quarter: *"our April 2026 acquisition of Qualified.com... our November 2025 acquisition of Informatica... and our October 2025 acquisition of Regrello."* It even quantifies one: the Informatica acquisition *"contributed approximately* ***$444 million*** *of total revenues"* this quarter, about **4.5** points of the **13.3%** growth. Strip the M&A and organic growth is roughly **\~9%**, consistent with the full-year trend (FY ending Jan 2026 revenue was **$41,525M**, **+9.58%**).
2. Net income is flattered above the operating line. Below operating income, the quarter carried a **$558M** net gain on strategic investments (vs a **$63M** loss a year ago, a **$621M** swing). It's two roughly equal halves: a **$268M** realized gain from exiting one private holding and a **$268M** unrealized mark-to-market gain on another (the filing also nets out **$119M** of impairments). Either way it's non-operating and largely non-recurring. It was partly offset by interest expense jumping to **$317M** from **$68M**. Salesforce took on new debt, including a **$6.0B** term loan drawn in March 2026, so total debt is now **\~$39.5B**. The cleaner profitability read is the **21.08%** operating margin, not net income.
3. The EPS lift came with a debt-funded buyback. Per the MD&A: *"Our* ***$25 billion*** *Accelerated Share Repurchase ('ASR Agreements') executed in March 2026 resulted in the repurchase of approximately 103 million shares in the period and benefitted our diluted net income per share by $0.14."* Where did the **$25B** come from? The same filing is explicit: *"In March 2026, we also issued unsecured Senior Notes with an aggregate principal of $25.0 billion... We used the net proceeds from the March 2026 Notes to fund an accelerated share repurchase program."* So Salesforce funded the entire buyback with newly issued debt, maturities stretching to 2066, to retire shares in March 2026, when the stock was well above today's **$158**. The diluted share count is genuinely down **\~10%** YoY (**870.7M** vs **969.2M**), which is real and shareholder-friendly; just know it was bought on the balance sheet, not purely with cash.
**What's really driving it: cRPO and buybacks**
For a subscription business the number that leads revenue is the contracted backlog, and that's the genuinely healthy signal:
* Current Remaining Performance Obligation (cRPO) **$33.6B**, **+14%** YoY. Contracted revenue to be recognized over the next 12 months.
* Total RPO **$67.9B**, **+11%** YoY
* Subscription & support is **\~95%** of revenue, recurring and sticky
* Operating cash flow was **$6.7B** in the quarter (Q1 is the seasonal collections peak) against capex of just **$145M** (**1.30%** of revenue). An asset-light cash machine throwing off roughly **$14B/yr** of free cash flow.
* Capital return is now core: the **$25B** ASR plus **$365M** of dividends in the quarter. Share count has fallen **971M** (Jan 2024) → **962M** → **929M** (Jan 2026) and again after the March ASR, to **\~819M** baseline following the upfront delivery of the recent ASR.
The honest framing is Salesforce has shifted from a growth story to a margin-expansion and capital-return story. Management is explicit: *"We are also focused on reducing our operating expenses to improve our operating margin."* While this mirrors the classic activist playbook (originally pressured by firms like Elliott and Starboard), it represents a stable, mature enterprise engine focused on efficiency over landing raw new logos.
**The biggest structural risk: the seat model, meet AI (their own words)**

Here's what should keep a CRM bull up at night, and it's the crux of the "SaaS crash" debate. Salesforce charges per human seat. The promise of AI agents, including its own Agentforce which is priced per "Agentic Work Unit (AWU)", is that software does work humans used to do. If that's real, customers may need fewer seats. Management flags exactly this in RiskFactors (Item 1A):
>"It is difficult to predict attrition rates given our varied customer base, the number of multi-year subscription contracts, and our shift toward consumption-based pricing models. Our attrition rates may increase or fluctuate as a result of various factors, including... decreases in the number of users at our customers... and economic downturns."
So Salesforce is simultaneously (a) selling AI as its next growth driver and (b) acknowledging a shift away from per-seat toward consumption-based pricing, quietly hedging the model it was built on! They also list the risk of *"any failure to expand our services and to develop and integrate our existing services in order to keep pace with technological developments."* Agentforce is both the answer to the AI threat and the thing that could cannibalize the seat count.
**The AI/Agentforce narrative is real, but mind the relabeling**
This quarter Salesforce reorganized its subscription reporting into two buckets:
* **Agentforce Apps** (**$6.91B | +9% YoY**):
* The rebrand: this is a renaming of the legacy core portfolio (Sales, Service, Marketing, and Commerce clouds) with Slack added in.
* The growth: despite the new AI-centric name, this bucket grew just **9%**, reflecting the maturity of the core CRM business.
* **Data 360, Headless Platform, & Other ($3.68B | +25% YoY)**:
* Constituents: includes Data 360, MuleSoft, Tableau, and the newly acquired Informatica.
* M&A impact: the high **25%** growth was heavily bolstered by Informatica, which contributed **$444** million of revenue this quarter.
Isolating "pure" AI revenue:
* **ARR vs. revenue**: the headline **$1.2 billion** Agentforce ARR (**+205%** YoY), a figure management reports in its earnings materials, not a line item in the 10-Q, is an annualized contract value, not the revenue actually recognized this quarter.
* **Monetization lag**: because Agentforce uses a consumption-based model, actual recognized revenue typically lags ARR by one to two quarters. Currently, Agentforce ARR is only **\~3%** of total annualized subscription revenue (**$1.2B** against **\~$42.4B** annualized).
**The takeaway**: don't read "**$6.9B** of Agentforce" into that first bucket, it's the rebranded core apps. The AI excitement is a product story and a fast growing but "tiny" ARR line, not yet a material recognized-revenue engine. Treat Agentforce as an unpriced option, not a current growth driver. Anyone modeling it as today's growth is modeling a rebrand plus a 3%-of-revenue contract base, not the income statement.
**Where the big money actually moved (13F filings, positions as of March 31, 2026)**
The cleanest fact first. Across the large 13F filers, aggregate shares held were roughly flat (**\~500M** shares, **-4.4%** YoY) while the dollar value of those holdings fell **\~33.5%** YoY. When shares are flat but value craters, it's the price that left, not the institutions. This wasn't a stampede for the exits.
Underneath that:
* The index complex is steady-to-higher: Vanguard **\~86.3M** → **88.1M** shares over eight quarters, BlackRock **74.6M** → **79.7M**, State Street \~flat at \~**50M**, Geode **19.5M** → **22.2M**. Passive money isn't going anywhere.
* The notable active move is a value shop stepping in: Harris Associates, a deep-value manager, cut to just **0.33M** shares in early 2025, then rebuilt to **14.92M** shares by March 2026. Value money buying the de-rating.
* What I won't consider as clear signals are the big jumps from Arrowstreet (**0.7M** → **12.7M**, a quant) and Morgan Stanley (**19M** → **31.7M**) that look like factor/inventory flow, not conviction. Flagging them here but they might not be a result of long-term hold.
**Caveat the lens honestly**: 13Fs only capture large institutional filers and reflect March 31, 2026 positions , before the most recent leg down, so this is neither every owner nor fully current. But the direction of the biggest holders is informative: indexers steady, a value manager accumulating, no broad institutional exit.
**Valuation is cheap vs its own history, but fairly priced once you count the debt**
At **$158.37** (June 26 close), with shares cut by the March ASR to **\~819M** (cover page), market cap is ≈ **$130B**. Add **$39.5B** total debt (including the **$6.0B** term loan drawn in March 2026), subtract **$11.8B** cash & marketable securities implies net debt of **\~$27.7B** and enterprise value ≈ **$157B**.
On a trailing-twelve-month (TTM) basis through Q1 2026 (Q2 25 + Q3 25 + Q4 25 + Q1 26): revenue **$42,829M**, net income **$8,023M**, diluted EPS **$8.63**.
* P/E (TTM) ≈ **18.4x** ($158.37 ÷ $8.63). Strip this quarter's one-time **$558M** gain (\~$0.49/sh after tax) and "core" TTM P/E is closer to **\~19.5x**.
* P/S ≈ **3.0x** ($130B ÷ $42.8B);
* EV/Sales ≈ **3.7x** ($157B ÷ $42.8B).
For context, that's a fraction of the double-digit sales multiple the market paid Salesforce at the 2021 software peak, the re-rating is the whole story. Today's multiple is roughly in line with slower-growth mature software, which is exactly the point of contention.
**In conclusion, here's what I keep going back and forth on:**
Salesforce's entire model is renting human seats. Its biggest bet, Agentforce, is a software designed to do work humans used to do. Those two things point in opposite directions: if Agentforce really works, does Salesforce sell more (every customer bolts agents on top of their seats) or less (customers quietly cut the seats the agents replace)?
**Figures from the 10-Q filed May 28, 2026 ( Q1 2026, ownership from 13F filings as of March 31, 2026; price as of the June 26,2026 close.**
**I expanded this into a** [full write-up on my Substack](https://open.substack.com/pub/secaura/p/the-case-on-salesforce-stock-crm?r=1jjx11&utm_campaign=post-expanded-share&utm_medium=web) **with the P/S de-rating chart, the debt-maturity schedule, the reverse-DCF, and the bull/bear scenario grid.**
**Disclaimer: This is an analysis of the SEC filings for educational. This is not financial advice. Do your own due diligence (DD).**
sentiment 1.00
2 days ago • u/Guilty_Glove9175 • r/whitecoatinvestor • canadian_accepted_to_usmd_uic_vs_u_of_t_pharmacy • C
Hi there. You sound terrified, and I understand no one wants to make the wrong decision. But if you really believe in yourself and work hard both career could be rewarding. If you are truly unsure of what you really want between MD and Pharmacy, you should take another year to think about. Maybe work in the mean time and volunteer at both to see how they work. As for me, I’ll say go for MD. Because if you are prudent, you could pay the loan off in 5-6 years once you become an attending. And after that you’ll make more money than a pharmacist. That is if you are worried about finances. As for schedules and lifestyle, medicine has changed and I can imagine for both md and pharmacist. There is no really good work life balance anymore because most of us are just working for a company now. So you are working based on whatever schedule. Another alternative would be to go to a Caribbean medical school, it’s cheaper but more inconvenient which is what I did. Ultimately, whatever decision you make, you have to be extremely steadfast because the journey is tumultuous. I started with 120 classmates. Only 8 made it to the end in 4 years. Some took longer but some never made it.
Wishing you all the best!
sentiment -0.41


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC